Fusion Pharm Stock Performance
| FSPM Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Fusion Pharm are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fusion Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Fusion Pharm is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:200 | Dividend Date 1998-02-27 | Last Split Date 2011-03-01 |
| Total Cashflows From Investing Activities | -23.3 K |
Fusion |
Fusion Pharm Relative Risk vs. Return Landscape
If you would invest 0.01 in Fusion Pharm on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Fusion Pharm or generate 0.0% return on investment over 90 days. Fusion Pharm is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Fusion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fusion Pharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fusion Pharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fusion Pharm, and traders can use it to determine the average amount a Fusion Pharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FSPM |
Based on monthly moving average Fusion Pharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fusion Pharm by adding Fusion Pharm to a well-diversified portfolio.
Fusion Pharm Fundamentals Growth
Fusion Stock prices reflect investors' perceptions of the future prospects and financial health of Fusion Pharm, and Fusion Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fusion Stock performance.
| Return On Asset | -1.38 | ||||
| Profit Margin | (1.11) % | ||||
| Operating Margin | (1.24) % | ||||
| Current Valuation | 294.4 K | ||||
| Shares Outstanding | 10.59 M | ||||
| Price To Earning | (0.07) X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 594.4 K | ||||
| Gross Profit | 34.19 K | ||||
| Net Income | (42.08 K) | ||||
| Cash And Equivalents | 1.45 K | ||||
| Total Debt | 1.2 K | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | 239.84 K | ||||
| Earnings Per Share | (0.15) X | ||||
| Total Asset | 4.04 K | ||||
| Retained Earnings | (9.11 K) | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 459 K | ||||
About Fusion Pharm Performance
By examining Fusion Pharm's fundamental ratios, stakeholders can obtain critical insights into Fusion Pharm's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Fusion Pharm is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Fusion Pharm performance evaluation
Checking the ongoing alerts about Fusion Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fusion Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 34.19 K. |
- Analyzing Fusion Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fusion Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Fusion Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fusion Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fusion Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fusion Pharm's stock. These opinions can provide insight into Fusion Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.